Drugs / Captopril
Captopril
also known as
Capoten · Acepril · Apopril · C09AA01 · Captomax · Captomex · Captoprilum · Ecopace · +16 more
Small molecule targets ACE via inhibition
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | CAPOTEN | — | 1982-10-25 – 1994-01-28 | fda.gov ↗ |
| Approved | US (FDA) | CAPOTEN | — | 1981-04-06 | fda.gov ↗ |
Trials 29 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06485661 | Jan → Sep 2024 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 0 | NCT03147092 | Feb 2018 → Jun 2020 | hypertensive disorder | Centro Neurológico de Pesquisa e Reabiitação, Brazil | Unknown | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT06292091 | Feb → Mar 2024 | hypertensive disorder | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01292694 | Mar 2011 → Mar 2017 | hypertensive disorder, pure autonomic failure | Vanderbilt University | Terminated | No outcome recorded |
| Phase 1 | NCT00240656 | Oct 2005 → May 2006 | pulmonary arterial hypertension | Hebei Medical University | Completed | No outcome recorded |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04629651 | Apr → Oct 2024 | myelofibrosis | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02770378 | Nov 2016 → Oct 2018 | glioblastoma | University of Ulm | Completed | No outcome recorded |
| Phase 1/2 | NCT03179163 | Jul 2016 → Aug 2022 | essential hypertension | Penn State University | Terminated | No outcome recorded |
| Phase 1/2 | NCT00086723 | Jul 2003 → Jan 2006 | cancer of unknown primary site | Northwestern University | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04578236 | Nov → Dec 2020 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT04355429 | May → Jul 2020 | COVID-19, pneumonia | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2 | NCT03613506 | Oct 2019 → Jun 2022 | — | Wuhan University | Unknown | No outcome recorded |
| Phase 2 | NCT00077064 | Jun 2003 → Nov 2008 | drug or radiation exposure-related interstitial lung disease, lung cancer | Radiation Therapy Oncology Group | Terminated | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT04345406 | Apr 2020 → Dec 2029 expected | COVID-19 | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03389724 | Nov 2017 → Nov 2021 | chemotherapy-induced toxicity, childhood acute myeloid leukemia | Children's Cancer Hospital Egypt 57357 | Completed | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | No outcome recorded |
| Phase 3 | NCT00004230 | Oct 1999 → Mar 2002 | cancer | Northwestern University | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT02817360 | Feb 2016 → Dec 2025 overdue | heart disorder, type 2 diabetes mellitus | Martin Huelsmann | Recruiting | No outcome recorded |
| Phase 4 | NCT01669434 | Jun 2015 → Nov 2016 | — | University of Nebraska | Completed | No outcome recorded |
| Phase 4 | NCT02217852 | Aug 2014 → Jan 2016 | hypertensive disorder | West China Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01545479 | Jan → Oct 2010 | kidney disorder | Instituto de Cardiologia do Rio Grande do Sul | Completed | No outcome recorded |
| Phase 4 | NCT01271478 | Aug 2009 → Dec 2010 | end stage renal failure | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 4 | NCT00660309 | Apr 2008 → Dec 2009 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00155064 | Jul 2002 → Dec 2005 | primary aldosteronism | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT04224675 | Mar 2020 → Mar 2023 | aneurysm or dilatation of ascending aorta | Onassis Cardiac Surgery Centre | Unknown | No outcome recorded |
| — | NCT03660293 | Apr 2017 → Jun 2019 | type 1 diabetes mellitus | Tanta University | Completed | No outcome recorded |
| — | NCT04371874 | Jan 2014 → Jul 2017 | hypertensive disorder | First Affiliated Hospital Xi'an Jiaotong University | Completed | No outcome recorded |
| — | NCT01867047 | Jun 2013 → Jun 2016 | hypotensive disorder | Duke University | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 25 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02941315 Background | Dec 2016 → Oct 2021 | idiopathic cardiomyopathy | RenJi Hospital | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01626469 Comparator | May 2012 → Sep 2020 | type 2 diabetes mellitus | Brigham and Women's Hospital | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05670028 Background | Jun 2023 → Jan 2026 | ischemic stroke, vascular insufficiency disorder | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00742040 Comparator | Aug 2008 → Aug 2009 | heart disorder | The Hospital for Sick Children | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00663949 Comparator | Feb 2006 → Dec 2007 | diabetic kidney disease | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT06141200 Comparator | Mar 2024 → Apr 2025 | essential hypertension | Natural Wellness Egypt | Unknown | No outcome recorded |
| Phase 3 | NCT06853951 Comparator | Jul 2023 → Mar 2025 overdue | chemotherapy-induced toxicity | Ain Shams University | Recruiting | No outcome recorded |
| Phase 3 | NCT06253429 Comparator | Jan 2023 → Jan 2024 | type 1 diabetes mellitus | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT03370705 Background | Jan → Dec 2019 | peripheral arterial occlusive disease 1 | Alfa Wassermann Tunisia | Unknown | No outcome recorded |
| Phase 3 | NCT01437371 Background | Aug 2011 → Jun 2014 | heart failure | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 410 trials | ||||||
| Phase 4 | NCT07547878 Comparator | Apr 2026 → Mar 2029 expected | chronic kidney disease, type 2 diabetes mellitus | Baylor Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07513883 Background | Mar 2026 → Sep 2028 expected | heart failure | Ziekenhuis Oost-Limburg | Recruiting | No outcome recorded |
| Phase 4 | NCT06417320 Comparator | Jun 2023 → Jan 2025 | nephrotic syndrome | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT04330300 Comparator | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded |
| Phase 4 | NCT04485845 Background | Nov 2019 → Aug 2020 | impaired renal function disease, metabolic syndrome X, type 2 diabetes mellitus | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04288700 Comparator | Oct 2019 → Dec 2020 | hemangioma | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT02200822 Comparator | Jul 2014 → Feb 2019 | heart failure | Hasselt University | Completed | No outcome recorded |
| Phase 4 | NCT01761916 Comparator | Jan → Jun 2013 | preeclampsia | Instituto Materno Infantil Prof. Fernando Figueira | Completed | No outcome recorded |
| Phase 4 | NCT00391846 Background | Oct 2006 → Jan 2009 | left ventricular failure | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00252317 Comparator | Nov 2005 → Oct 2008 | aortic valve stenosis | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07272486 Background | Aug 2024 → Jul 2025 | essential hypertension, hypertensive urgency | Ankara City Hospital Bilkent | Completed | No outcome recorded |
| — | NCT04893629 Comparator | May 2021 → Nov 2024 | cardiomyopathy | Damascus University | Terminated | No outcome recorded |
| — | NCT05064904 Comparator | Feb 2019 → Jan 2024 | acute kidney injury | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT00292162 Comparator | Jan 2007 → Jul 2009 | atrial fibrillation, heart failure | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 55 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | captopril | “Examples of possible ACE-I drugs include:
benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗53“To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or...” NCT05670028 ↗ “The study will be a randomized, double-blind trial. Patients will be randomized into one of two parallel arms, receiving captopril or atenolol.” NCT04224675 ↗ “Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril” NCT04330300 ↗ “ACE inhibitor: enalapril, lisinopril, ramipril, captopril or trandolapril” NCT07513883 ↗ “Taking captopril 12.5mg b.i.d for two months before radiotherapy.” NCT03613506 ↗ “captopril: 50 mg tid→25 mg tid→12,5 mg tid→6,25 mg tid→stop” NCT02200822 ↗ “benazepril, captopril, enalapril, fosinopril, lisinopril” NCT00684489 ↗ “equal to Losartan 50mg or Captopril 25mg bid” NCT05064904 ↗ “Etiology treatment, captopril, beta-blocker” NCT02941315 ↗ “Captopril, beta-blocker” NCT02941315 ↗ “Captopril or equivalent” NCT03370705 ↗ “Captopril or enalapril” NCT04345406 ↗ “Captopril, forxiga” NCT06417320 ↗ “Captopril 150mg/d” NCT02817360 ↗ “captopril” NCT01669434 ↗ “Captopril” NCT06853951 ↗ “Captopril” NCT02735707 ↗ |
| Known as | Acepril | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Apopril | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | C09AA01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Capoten | “Examples of possible ACE-I drugs include: benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗ |
| Known as | Captomax | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Captomex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Captoprilum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Ecopace | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Farcopril | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Garranil | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Hypopress | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Hyteneze 12.5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Hyteneze 25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Hyteneze 50 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Kaplon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Lopril | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Mepha | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Noyada | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | NSC-757419 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | SA-333 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | SQ -14225 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Tensiomin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Tensobon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Known as | Zapto | ChEMBL registry synonym — accepted as the source's own label CHEMBL1560 ↗ |
| Action | Inhibit | “captopril (angiotensin-converting enzyme inhibition)” NCT00155064 ↗ |
| Modality | Small molecule | — CHEMBL1560 ↗ |
| Route | Oral | “Patients receive oral captopril 2 to 3 times daily” NCT00004230 ↗ |
| Target | ACE | “A study on hypertensive rats demonstrated that using ACE inhibitors(captopril) abolished and attenuated the effect of dihydrotestosterone (DHT).” NCT04578236 ↗ |